<i>BRCA1</i>-Associated Breast Cancers Present Differently From <i>BRCA2</i>-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study
Adriana J. Rijnsburger(Radboud University Nijmegen), Jan G.M. Klijn(German Cancer Research Center), Emiel J. Rutgers(Oncode Institute), Mieke Kriege, Rob A.�E.�M. Tollenaar(Leiden University Medical Center), Hans Peterse(The Netherlands Cancer Institute), Theo M. de Kok(Erasmus MC Cancer Institute), Martin N.J.M. Wasser(Leiden University Medical Center), Claudette E. Loo(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Maartje J. Hooning(Erasmus MC Cancer Institute), Inge‐Marie Obdeijn(Erasmus MC), Harry J. de Koning(Erasmus MC), C. Boetes(Radboud University Nijmegen), Paul Schmitz(University Hospital Regensburg), R. Kaas(Radboud University Nijmegen), Caroline Seynaeve(Radboud University Nijmegen), Jan C. Oosterwijk(University Medical Center Groningen), Carina C. M. Bartels(Radboud University Nijmegen), Madeleine M.A. Tilanus‐Linthorst(Erasmus University Rotterdam), Sybren Meijer(Erasmus MC Cancer Institute), Sara Müller(Arthritis UK), Elisabeth Bergers(Alkermes (Ireland))
Cited by 181
Related Papers
American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography
|CA A Cancer Journal for Clinicians|2007|2.6k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition
|New England Journal of Medicine|2004|1.7k